ID   HNF1B_HUMAN             Reviewed;         557 AA.
AC   P35680; B4DKM3;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   21-MAR-2012, entry version 140.
DE   RecName: Full=Hepatocyte nuclear factor 1-beta;
DE            Short=HNF-1-beta;
DE            Short=HNF-1B;
DE   AltName: Full=Homeoprotein LFB3;
DE   AltName: Full=Transcription factor 2;
DE            Short=TCF-2;
DE   AltName: Full=Variant hepatic nuclear factor 1;
DE            Short=vHNF1;
GN   Name=HNF1B; Synonyms=TCF2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Liver;
RX   MEDLINE=91305097; PubMed=1677179; DOI=10.1093/nar/19.13.3553;
RA   Bach I., Mattei M.-G., Cereghini S., Yaniv M.;
RT   "Two members of an HNF1 homeoprotein family are expressed in human
RT   liver.";
RL   Nucleic Acids Res. 19:3553-3559(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A; B AND C).
RC   TISSUE=Liver;
RX   MEDLINE=94038905; PubMed=7900999;
RA   Bach I., Yaniv M.;
RT   "More potent transcriptional activators or a transdominant inhibitor
RT   of the HNF1 homeoprotein family are generated by alternative RNA
RT   processing.";
RL   EMBO J. 12:4229-4242(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=98061083; PubMed=9398836; DOI=10.1038/ng1297-384;
RA   Horikawa Y., Iwasaki N., Hara M., Furuta H., Hinokio Y.,
RA   Cockburn B.N., Lindner T., Yamagata K., Ogata M., Tomonaga O.,
RA   Kuroki H., Kasahara T., Iwamoto Y., Bell G.I.;
RT   "Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated
RT   with MODY.";
RL   Nat. Genet. 17:384-385(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM B).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INVOLVEMENT IN RCAD.
RX   PubMed=10484768; DOI=10.1093/hmg/8.11.2001;
RA   Lindner T.H., Njoelstad P.R., Horikawa Y., Bostad L., Bell G.I.,
RA   Soevik O.;
RT   "A novel syndrome of diabetes mellitus, renal dysfunction and genital
RT   malformation associated with a partial deletion of the pseudo-POU
RT   domain of hepatocyte nuclear factor-1beta.";
RL   Hum. Mol. Genet. 8:2001-2008(1999).
RN   [7]
RP   STRUCTURE BY NMR OF 233-321.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the homeobox domain of hepatocyte nuclear
RT   factor 1-beta (HNF-1beta).";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [8]
RP   VARIANT RCAD THR-241, AND VARIANT DIABETES SER-492.
RX   PubMed=10672455; DOI=10.1007/s001250050018;
RA   Weng J.P., Lehto M., Forsblom C., Huang X., Li H., Groop L.C.;
RT   "Hepatocyte nuclear factor-1 beta (MODY5) gene mutations in
RT   Scandinavian families with early-onset diabetes or kidney disease or
RT   both.";
RL   Diabetologia 43:131-132(2000).
RN   [9]
RP   VARIANT RCAD PHE-36, AND CHARACTERIZATION OF VARIANT RCAD PHE-36.
RX   PubMed=11845238; DOI=10.1007/s125-002-8259-5;
RA   Yoshiuchi I., Yamagata K., Zhu Q., Tamada I., Takahashi Y.,
RA   Onigata K., Takeda J., Miyagawa J., Matsuzawa Y.;
RT   "Identification of a gain-of-function mutation in the HNF-1beta gene
RT   in a Japanese family with MODY.";
RL   Diabetologia 45:154-155(2002).
RN   [10]
RP   VARIANT RCAD PRO-151.
RX   PubMed=11918730; DOI=10.1046/j.1523-1755.2002.00272.x;
RA   Bingham C., Ellard S., Cole T.R.P., Jones K.E., Allen L.I.S.,
RA   Goodship J.A., Goodship T.H.J., Bakalinova-Pugh D., Russell G.I.,
RA   Woolf A.S., Nicholls A.J., Hattersley A.T.;
RT   "Solitary functioning kidney and diverse genital tract malformations
RT   associated with hepatocyte nuclear factor-1beta mutations.";
RL   Kidney Int. 61:1243-1251(2002).
RN   [11]
RP   VARIANT NIDDM ARG-465.
RX   PubMed=12161522; DOI=10.1210/jc.87.8.3859;
RA   Furuta H., Furuta M., Sanke T., Ekawa K., Hanabusa T., Nishi M.,
RA   Sasaki H., Nanjo K.;
RT   "Nonsense and missense mutations in the human hepatocyte nuclear
RT   factor-1 beta gene (TCF2) and their relation to type 2 diabetes in
RT   Japanese.";
RL   J. Clin. Endocrinol. Metab. 87:3859-3863(2002).
RN   [12]
RP   VARIANT RCAD ASP-260, AND CHARACTERIZATION OF VARIANT RCAD ASP-260.
RX   PubMed=14583183; DOI=10.1016/S1056-8727(02)00221-0;
RA   So W.Y., Ng M.C.Y., Horikawa Y., Njoelstad P.R., Li J.K.Y., Ma R.C.W.,
RA   Bell G.I., Chan J.C.N.;
RT   "Genetic variants of hepatocyte nuclear factor-1beta in Chinese young-
RT   onset diabetic patients with nephropathy.";
RL   J. Diabetes Complications 17:369-373(2003).
RN   [13]
RP   VARIANTS RCAD PRO-112; GLU-136; GLN-164; HIS-165 AND HIS-295.
RX   PubMed=15068978;
RA   Bellanne-Chantelot C., Chauveau D., Gautier J.-F., Dubois-Laforgue D.,
RA   Clauin S., Beaufils S., Wilhelm J.-M., Boitard C., Noeel L.-H.,
RA   Velho G., Timsit J.;
RT   "Clinical spectrum associated with hepatocyte nuclear factor-1beta
RT   mutations.";
RL   Ann. Intern. Med. 140:510-517(2004).
RN   [14]
RP   VARIANT RCAD ASN-153, AND CHARACTERIZATION OF VARIANT RCAD ASN-153.
RX   PubMed=15001636; DOI=10.1210/jc.2003-031308;
RA   Kitanaka S., Miki Y., Hayashi Y., Igarashi T.;
RT   "Promoter-specific repression of hepatocyte nuclear factor (HNF)-1beta
RT   and HNF-1alpha transcriptional activity by an HNF-1beta missense
RT   mutant associated with type 5 maturity-onset diabetes of the young
RT   with hepatic and biliary manifestations.";
RL   J. Clin. Endocrinol. Metab. 89:1369-1378(2004).
RN   [15]
RP   VARIANT RCAD TRP-148.
RX   PubMed=15181075; DOI=10.1210/jc.2003-031828;
RA   Yorifuji T., Kurokawa K., Mamada M., Imai T., Kawai M., Nishi Y.,
RA   Shishido S., Hasegawa Y., Nakahata T.;
RT   "Neonatal diabetes mellitus and neonatal polycystic, dysplastic
RT   kidneys: phenotypically discordant recurrence of a mutation in the
RT   hepatocyte nuclear factor-1beta gene due to germline mosaicism.";
RL   J. Clin. Endocrinol. Metab. 89:2905-2908(2004).
RN   [16]
RP   VARIANTS RCAD CYS-76; PRO-112; GLU-136; GLN-164; HIS-165; GLN-235;
RP   GLY-276; ASP-285; CYS-295; HIS-295 AND SER-370.
RX   PubMed=16249435; DOI=10.2337/diabetes.54.11.3126;
RA   Bellanne-Chantelot C., Clauin S., Chauveau D., Collin P., Daumont M.,
RA   Douillard C., Dubois-Laforgue D., Dusselier L., Gautier J.-F.,
RA   Jadoul M., Laloi-Michelin M., Jacquesson L., Larger E., Louis J.,
RA   Nicolino M., Subra J.-F., Wilhem J.-M., Young J., Velho G., Timsit J.;
RT   "Large genomic rearrangements in the hepatocyte nuclear factor-1beta
RT   (TCF2) gene are the most frequent cause of maturity-onset diabetes of
RT   the young type 5.";
RL   Diabetes 54:3126-3132(2005).
RN   [17]
RP   VARIANTS RCAD GLY-61; GLY-110; LEU-148; GLU-156; GLN-276 AND PRO-295.
RX   PubMed=15930087; DOI=10.1136/jmg.2005.032854;
RA   Edghill E.L., Bingham C., Ellard S., Hattersley A.T.;
RT   "Mutations in hepatocyte nuclear factor-1beta and their related
RT   phenotypes.";
RL   J. Med. Genet. 43:84-90(2006).
RN   [18]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO HEREDITARY PROSTATE CANCER.
RX   PubMed=18264097; DOI=10.1038/ng.90;
RG   The UK genetic prostate cancer study collaborators;
RG   British association of urological surgeons section of oncology;
RG   The UK protecT study collaborators;
RA   Eeles R.A., Kote-Jarai Z., Giles G.G., Al Olama A.A., Guy M.,
RA   Jugurnauth S.K., Mulholland S., Leongamornlert D.A., Edwards S.M.,
RA   Morrison J., Field H.I., Southey M.C., Severi G., Donovan J.L.,
RA   Hamdy F.C., Dearnaley D.P., Muir K.R., Smith C., Bagnato M.,
RA   Ardern-Jones A.T., Hall A.L., O'Brien L.T., Gehr-Swain B.N.,
RA   Wilkinson R.A., Cox A., Lewis S., Brown P.M., Jhavar S.G.,
RA   Tymrakiewicz M., Lophatananon A., Bryant S.L., Horwich A.,
RA   Huddart R.A., Khoo V.S., Parker C.C., Woodhouse C.J., Thompson A.,
RA   Christmas T., Ogden C., Fisher C., Jamieson C., Cooper C.S.,
RA   English D.R., Hopper J.L., Neal D.E., Easton D.F.;
RT   "Multiple newly identified loci associated with prostate cancer
RT   susceptibility.";
RL   Nat. Genet. 40:316-321(2008).
CC   -!- FUNCTION: Transcription factor, probably binds to the inverted
CC       palindrome 5'-GTTAATNATTAAC-3'.
CC   -!- SUBUNIT: Binds DNA as a dimer. Can form homodimer or heterodimer
CC       with HNF1-alpha.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=P35680-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P35680-2; Sequence=VSP_002254;
CC       Name=C;
CC         IsoId=P35680-3; Sequence=VSP_002255, VSP_002256;
CC   -!- DISEASE: Defects in HNF1B are the cause of renal cysts and
CC       diabetes syndrome (RCAD) [MIM:137920]; also called maturity-onset
CC       diabetes of the young type 5 (MODY5) or familial hypoplastic
CC       glomerulocystic kidney disease (GCKD). RCAD is an autosomal
CC       dominant disorder comprising non-diabetic renal disease resulting
CC       from abnormal renal development, and diabetes, which in some cases
CC       occurs earlier than age 25 years and is thus consistent with a
CC       diagnosis of maturity-onset diabetes of the young (MODY5). The
CC       renal disease is highly variable and includes renal cysts,
CC       glomerular tufts, aberrant nephrogenesis, primitive tubules,
CC       irregular collecting systems, oligomeganephronia, enlarged renal
CC       pelves, abnormal calyces, small kidney, single kidney, horseshoe
CC       kidney, and hyperuricemic nephropathy.
CC   -!- DISEASE: Defects in HNF1B may be rare genetic risk factor
CC       contributing to the development of non-insulin-dependent diabetes
CC       mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an
CC       autosomal dominant mode of inheritance, onset during adulthood and
CC       insulin resistance.
CC   -!- DISEASE: Defects in HNF1B may be a cause of susceptibility to
CC       prostate cancer hereditary type 11 (HPC11) [MIM:611955]. It is a
CC       condition associated with familial predisposition to cancer of the
CC       prostate. Most prostate cancers are adenocarcinomas that develop
CC       in the acini of the prostatic ducts. Other rare histopathologic
CC       types of prostate cancer that occur in approximately 5% of
CC       patients include small cell carcinoma, mucinous carcinoma,
CC       prostatic ductal carcinoma, transitional cell carcinoma, squamous
CC       cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma
CC       (basaloid), signet-ring cell carcinoma and neuroendocrine
CC       carcinoma.
CC   -!- SIMILARITY: Belongs to the HNF1 homeobox family.
CC   -!- SIMILARITY: Contains 1 homeobox DNA-binding domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/HNF1B";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Hepatocyte nuclear factors
CC       entry;
CC       URL="http://en.wikipedia.org/wiki/Hepatocyte_nuclear_factors";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X58840; CAA41652.1; -; mRNA.
DR   EMBL; X71348; CAB59223.1; -; mRNA.
DR   EMBL; U90287; AAC63388.1; -; Genomic_DNA.
DR   EMBL; U90279; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90280; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90281; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90282; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90283; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90284; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90285; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; U90286; AAC63388.1; JOINED; Genomic_DNA.
DR   EMBL; AK296633; BAG59235.1; -; mRNA.
DR   EMBL; BC017714; AAH17714.1; -; mRNA.
DR   IPI; IPI00020078; -.
DR   IPI; IPI00219911; -.
DR   IPI; IPI00219912; -.
DR   PIR; S34412; S34412.
DR   RefSeq; NP_000449.1; NM_000458.2.
DR   RefSeq; NP_001159395.1; NM_001165923.1.
DR   UniGene; Hs.191144; -.
DR   PDB; 2DA6; NMR; -; A=233-321.
DR   PDB; 2H8R; X-ray; 3.20 A; A/B=91-310.
DR   PDBsum; 2DA6; -.
DR   PDBsum; 2H8R; -.
DR   ProteinModelPortal; P35680; -.
DR   SMR; P35680; 1-32, 91-325.
DR   IntAct; P35680; 1.
DR   STRING; P35680; -.
DR   PhosphoSite; P35680; -.
DR   DMDM; 547664; -.
DR   PRIDE; P35680; -.
DR   DNASU; 6928; -.
DR   Ensembl; ENST00000225893; ENSP00000225893; ENSG00000108753.
DR   GeneID; 6928; -.
DR   KEGG; hsa:6928; -.
DR   UCSC; uc002hok.2; human.
DR   CTD; 6928; -.
DR   GeneCards; GC17M036046; -.
DR   H-InvDB; HIX0013750; -.
DR   HGNC; HGNC:11630; HNF1B.
DR   HPA; HPA002083; -.
DR   MIM; 125853; phenotype.
DR   MIM; 137920; phenotype.
DR   MIM; 189907; gene.
DR   MIM; 611955; phenotype.
DR   neXtProt; NX_P35680; -.
DR   Orphanet; 261265; 17q12 microdeletion syndrome.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 73217; Mullerian aplasia.
DR   Orphanet; 93111; Renal cysts and diabetes syndrome.
DR   PharmGKB; PA162391083; -.
DR   eggNOG; NOG79356; -.
DR   GeneTree; ENSGT00530000063140; -.
DR   HOGENOM; HBG445326; -.
DR   HOVERGEN; HBG005980; -.
DR   InParanoid; P35680; -.
DR   KO; K08034; -.
DR   OMA; SLDPGHN; -.
DR   OrthoDB; EOG43BMNN; -.
DR   PhylomeDB; P35680; -.
DR   Pathway_Interaction_DB; hnf3bpathway; FOXA2 and FOXA3 transcription factor networks.
DR   Reactome; REACT_111045; Developmental Biology.
DR   NextBio; 27109; -.
DR   ArrayExpress; P35680; -.
DR   Bgee; P35680; -.
DR   CleanEx; HS_HNF1B; -.
DR   Genevestigator; P35680; -.
DR   GermOnline; ENSG00000108753; Homo sapiens.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0003700; F:sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:UniProtKB.
DR   GO; GO:0048806; P:genitalia development; IMP:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IMP:UniProtKB.
DR   GO; GO:0060261; P:positive regulation of transcription initiation from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-dependent; IDA:UniProtKB.
DR   GO; GO:0039020; P:pronephric nephron tubule development; IGI:UniProtKB.
DR   GO; GO:0035565; P:regulation of pronephros size; IMP:UniProtKB.
DR   InterPro; IPR006899; HNF-1_N.
DR   InterPro; IPR023219; HNF1_dimer_dom.
DR   InterPro; IPR006897; HNF1b_C.
DR   InterPro; IPR001356; Homeodomain.
DR   InterPro; IPR009057; Homeodomain-like.
DR   InterPro; IPR010982; Lambda_DNA-bd.
DR   Gene3D; G3DSA:1.10.260.40; G3DSA:1.10.260.40; 1.
DR   Gene3D; G3DSA:1.10.10.60; Homeodomain-rel; 1.
DR   Pfam; PF04814; HNF-1_N; 1.
DR   Pfam; PF04812; HNF-1B_C; 1.
DR   Pfam; PF00046; Homeobox; 1.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF100957; HNF1_dimer_dom; 1.
DR   SUPFAM; SSF46689; Homeodomain_like; 1.
DR   SUPFAM; SSF47413; Lambda_like_DNA; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Complete proteome;
KW   Diabetes mellitus; DNA-binding; Homeobox; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    557       Hepatocyte nuclear factor 1-beta.
FT                                /FTId=PRO_0000049121.
FT   DNA_BIND    231    311       Homeobox; HNF1-type.
FT   REGION        1     31       Dimerization (By similarity).
FT   MOD_RES      75     75       Phosphoserine (By similarity).
FT   MOD_RES      80     80       Phosphoserine (By similarity).
FT   VAR_SEQ     183    208       Missing (in isoform B).
FT                                /FTId=VSP_002254.
FT   VAR_SEQ     350    400       VRYSQQGNNEITSSSTISHHGNSAMVTSQSVLQQVSPASLD
FT                                PGHNLLSPDG -> KQRLGLTASATQPSWFLPRILSGLRVF
FT                                RGANAFEMILGPLSHCQNILPWK (in isoform C).
FT                                /FTId=VSP_002255.
FT   VAR_SEQ     401    557       Missing (in isoform C).
FT                                /FTId=VSP_002256.
FT   VARIANT      36     36       S -> F (in RCAD; gain-of-function
FT                                mutation).
FT                                /FTId=VAR_046012.
FT   VARIANT      61     61       V -> G (in RCAD).
FT                                /FTId=VAR_046013.
FT   VARIANT      76     76       G -> C (in RCAD).
FT                                /FTId=VAR_046014.
FT   VARIANT     110    110       V -> G (in RCAD).
FT                                /FTId=VAR_046015.
FT   VARIANT     112    112       R -> P (in RCAD).
FT                                /FTId=VAR_046016.
FT   VARIANT     136    136       Q -> E (in RCAD).
FT                                /FTId=VAR_046017.
FT   VARIANT     148    148       S -> L (in RCAD).
FT                                /FTId=VAR_046018.
FT   VARIANT     148    148       S -> W (in RCAD).
FT                                /FTId=VAR_046019.
FT   VARIANT     151    151       S -> P (in RCAD).
FT                                /FTId=VAR_046020.
FT   VARIANT     153    153       H -> N (in RCAD).
FT                                /FTId=VAR_046021.
FT   VARIANT     156    156       K -> E (in RCAD; has diminished
FT                                transcriptional activity by loss of DNA
FT                                binding activity).
FT                                /FTId=VAR_046022.
FT   VARIANT     164    164       K -> Q (in RCAD).
FT                                /FTId=VAR_046023.
FT   VARIANT     165    165       R -> H (in RCAD).
FT                                /FTId=VAR_046024.
FT   VARIANT     235    235       R -> Q (in RCAD).
FT                                /FTId=VAR_046025.
FT   VARIANT     241    241       A -> T (in RCAD).
FT                                /FTId=VAR_046026.
FT   VARIANT     260    260       E -> D (in RCAD; insignificant
FT                                differences in transactivation ability
FT                                between wild-type and mutated HNF1B).
FT                                /FTId=VAR_046027.
FT   VARIANT     276    276       R -> G (in RCAD).
FT                                /FTId=VAR_046028.
FT   VARIANT     276    276       R -> Q (in RCAD).
FT                                /FTId=VAR_046029.
FT   VARIANT     285    285       G -> D (in RCAD).
FT                                /FTId=VAR_046030.
FT   VARIANT     295    295       R -> C (in RCAD).
FT                                /FTId=VAR_046031.
FT   VARIANT     295    295       R -> H (in RCAD).
FT                                /FTId=VAR_046032.
FT   VARIANT     295    295       R -> P (in RCAD).
FT                                /FTId=VAR_046033.
FT   VARIANT     370    370       G -> S (in RCAD).
FT                                /FTId=VAR_046034.
FT   VARIANT     465    465       S -> R (in NIDDM; 22% reduction in
FT                                activity).
FT                                /FTId=VAR_017665.
FT   VARIANT     492    492       G -> S (in diabetes; early onset
FT                                association; uncertain pathogenicity;
FT                                dbSNP:rs1805035).
FT                                /FTId=VAR_012058.
FT   HELIX        91     98
FT   HELIX       101    113
FT   HELIX       118    132
FT   HELIX       136    143
FT   HELIX       147    154
FT   HELIX       162    181
FT   TURN        182    185
FT   HELIX       240    252
FT   HELIX       258    275
FT   HELIX       283    286
FT   HELIX       293    304
FT   HELIX       311    315
SQ   SEQUENCE   557 AA;  61324 MW;  9E1ECC7423B73980 CRC64;
     MVSKLTSLQQ ELLSALLSSG VTKEVLVQAL EELLPSPNFG VKLETLPLSP GSGAEPDTKP
     VFHTLTNGHA KGRLSGDEGS EDGDDYDTPP ILKELQALNT EEAAEQRAEV DRMLSEDPWR
     AAKMIKGYMQ QHNIPQREVV DVTGLNQSHL SQHLNKGTPM KTQKRAALYT WYVRKQREIL
     RQFNQTVQSS GNMTDKSSQD QLLFLFPEFS QQSHGPGQSD DACSEPTNKK MRRNRFKWGP
     ASQQILYQAY DRQKNPSKEE REALVEECNR AECLQRGVSP SKAHGLGSNL VTEVRVYNWF
     ANRRKEEAFR QKLAMDAYSS NQTHSLNPLL SHGSPHHQPS SSPPNKLSGV RYSQQGNNEI
     TSSSTISHHG NSAMVTSQSV LQQVSPASLD PGHNLLSPDG KMISVSGGGL PPVSTLTNIH
     SLSHHNPQQS QNLIMTPLSG VMAIAQSLNT SQAQSVPVIN SVAGSLAALQ PVQFSQQLHS
     PHQQPLMQQS PGSHMAQQPF MAAVTQLQNS HMYAHKQEPP QYSHTSRFPS AMVVTDTSSI
     STLTNMSSSK QCPLQAW
//
